Lineage Cell Therapeutics Inc (LCTX): רווח למניה בשנים עשר החודשים האחרונים

The trailing twelve-month earnings per share for Lineage Cell Therapeutics (LCTX) shows that the metric stands at -0.18. This trend is driven by the outsourcing of production and testing to third-party contractors to maintain flexibility. Stability is supported by grants and holding company assistance during planned resource expenditure. The absence of seasonality and cyclicality makes the business resilient, as development is tied to clinical trial stages.

Lineage Cell Therapeutics' status as a reputable innovator in cell therapy allows for the assessment of its scientific effectiveness through the monetization of intellectual capital. Net income per share over 12 months, calculated by dividing total income by the number of outstanding shares, determines the intrinsic value of the business; therefore, analyzing the trend of annual net income per share is critical for minimizing the risk of capital losses.